根治性切除的非小细胞肺癌中的鸟氨酸脱羧酶 mRNA 表达。

Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.

机构信息

Department of General, Visceral and Cancer Surgery, University of Cologne, Germany.

出版信息

Clin Lung Cancer. 2010 Mar 1;11(2):114-9. doi: 10.3816/CLC.2010.n.015.

DOI:10.3816/CLC.2010.n.015

PMID:20199977

Abstract

BACKGROUND

The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC.

PATIENTS AND METHODS

A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative real-time reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected.

RESULTS

Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor.

CONCLUSION

In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted.

摘要

背景

鸟氨酸脱羧酶（ODC）在非小细胞肺癌（NSCLC）发病机制中的作用仍未得到充分研究。因此，本研究旨在探讨 ODCmRNA 表达作为可切除 NSCLC 患者预后生物标志物的潜在作用。

患者和方法

使用定量实时逆转录聚合酶链反应方法分析了 91 例 NSCLC 患者的肿瘤和配对非肿瘤肺组织样本。使用β-肌动蛋白作为参比基因测量肿瘤和非肿瘤肺组织中的相对 ODCmRNA 表达。43 例患者（47%）为鳞状细胞癌，33 例（36%）为腺癌，15 例（17%）为大细胞癌。所有患者的疾病均为 R0 切除。

结果

在所有 91 例肿瘤和非肿瘤肺组织样本中均检测到 ODC。与非肿瘤肺组织中 ODC 的中位数表达 7.89（范围，0.0-45.8）相比，肿瘤中 9.11（范围，0.92-155.35）的中位数表达显著升高。ODC 表达水平与任何临床病理参数均无关。使用 ODC/β-肌动蛋白比值为 10 作为截断值，肿瘤 ODC（tODC）表达是非小细胞肺癌的显著预后因素。肿瘤和非肿瘤表达之间的 ODC 比值甚至更具预后意义。此外，Cox 比例风险模型分析表明 ODC 表达是非独立的预后因素。

结论

在这项研究中，ODC 显示出在 NSCLC 中有预后潜力。tODC 表达水平较低与更具侵袭性的肿瘤生物学相关。此外，在癌变过程中 ODCmRNA 表达的增加似乎具有有利的预后作用。测量 NSCLC 患者的 ODC 表达可能有助于进一步的化疗决策。我们的研究结果表明，进一步研究 NSCLC 中 ODCmRNA 表达可能是必要的。